Cheating,
or an Early Mingling of the Blood?
New York Times
By GINA KOLATA
May 10, 2005
Last month, when the champion American cyclist Tyler Hamilton was
accused of blood doping, or transfusing himself with another person's
blood to increase his oxygen-carrying red cells, he offered a
surprising defense: the small amount of different blood found mixed in
with his own must have come from a "vanishing twin."
In other words, his scientific expert argued, Mr. Hamilton had a
twin that died in utero but, before dying, contributed some blood cells
to him during fetal life. And those cells remained in his body,
producing blood that matched the dead twin and not Mr. Hamilton. Or
perhaps it was his mother's blood that got mixed in during fetal life.
An arbitration panel did not believe those hypotheses and said
there was a "negligible probability" that Mr. Hamilton was anything but
guilty.
The test, they concluded in a 2-to-1 decision, shows a blood
transfusion and that meant that Mr. Hamilton was suspended from racing
for two years, the first and only person convicted for that offense. At
age 34, near the end of his career, it could mean his championship days
are over.
Mr. Hamilton has said he will appeal the decision. If he can
prove the test was flawed, then not only might he return to cycling and
his multimillion-dollar career, but other athletes could use the same
defense. The new test, developed over two years by the World
Anti-Doping Agency and the United States Anti-Doping Agency, would be
all but useless.
Travis T. Tygart, the general counsel for the United States Anti-Doping
Agency, which prosecuted Mr. Hamilton, says the scientific evidence was
against the cyclist.
"Our interest is only justice," Mr. Tygart said. "We don't blindly
bring doping cases. We look at the evidence, and if we think there is
enough evidence to go forward we present that to an arbitration panel."
Whether Mr. Hamilton is guilty or innocent, his defense does
refer to a real phenomenon. Researchers who have no involvement in Mr.
Hamilton's case say it actually is possible for someone to have two
types of blood in his body, without doping. They emphasize that they do
not know whether this is the case with Mr. Hamilton.
One route to this odd state, called chimerism, is the vanishing twin.
Dr. Helain Landy of Georgetown University, who has no involvement in
the Hamilton case, has found that 20 to 30 percent of pregnancies that
start out as twins end up as single babies, with one twin being
absorbed by the mother during the first trimester.
Others researchers have found that in some cases, before the twin
is absorbed, some of its cells enter the body of the other fetus and
remain there for life. The cells can include bone marrow stem cells,
the progenitors of blood cells.
Another route to chimerism is through the cells that routinely pass
from a mother to fetus and remain there for life.
Dr. Ann Reed, chairwoman of rheumatology research at the Mayo Clinic,
who uses sensitive DNA tests to look for chimerism, finds that about 50
to 70 percent of healthy people are chimeras. The more scientists look
for chimerism, the more they find it. It seemed not to exist in the
past, she said, because no one was explicitly looking for small amounts
of foreign cells in people's bodies.
"Some believe that if you look hard enough you can find chimerism in
anybody," said Dr. Reed, who also has not been involved in the Hamilton
case. It is so common that she thinks there must be a biological reason
for it. It also may cause problems, she and others say.
Chimerism may be why bone marrow from a seemingly perfectly
matched donor relentlessly attacks a patient who receives it in a
transplant - the attackers may be a small percentage of cells in the
marrow that come from someone else. It also may help explain autoimmune
diseases, when the body's own immune cells attack. The attacking cells
may be the foreign ones that arise from someone else.
The Hamilton case involves a test developed by Dr. Margaret Nelson and
her colleagues at the Royal Prince Alfred Hospital in Australia. It was
based on a simple idea: if an athlete got a transfusion, he would have
to make sure the blood was the right match using the blood antigens A,
B and O. But blood cells have other surface proteins, so-called minor
antigens, that do not matter in blood typing for transfusions but can
be used to distinguish one person's blood from another's. The
investigators said they could use a sensitive test, flow cytometry, to
search for small amounts of blood with minor antigens different from
those in the athlete's own blood.
It was an important advance, anti-doping agency officials said.
They knew that athletes, including cyclists, had used blood
transfusions in the past to boost their performance but had no test to
prove it.
The principal hematologist working with the anti-doping agencies,
Dr. Ross Brown of Royal Prince Alfred Hospital, rejects the idea that
the test could be finding chimeras instead of transfusions. In his
testimony at Mr. Hamilton's hearing and in an e-mail message Dr. Brown,
who is Dr. Nelson's immediate supervisor, said chimerism was so rare as
to be inconceivable as an explanation for Mr. Hamilton's results. "The
only reasonable explanation is a transfusion," he wrote by e-mail.
Dr. Brown, the only outside scientist that the anti-doping agency
suggested to present its point of view, said that blood banks almost
never found chimeras. The blood banks used a less sensitive test, but
Dr. Brown testified that he himself, using the more sensitive flow
cytometry on at least 20,000 blood samples, never found a chimera.
And, he said, reports of people with small amounts of foreign
cells do not signify that an athlete with a second population of blood
cells had someone else's blood stem cells in his bone marrow. Moreover,
he said, Mr. Hamilton tested negative a few months after his positive
test last fall. That is consistent with an athlete who had
transfusions, was caught, and then stopped.
In addition, Dr. Brown said, another rider on Mr. Hamilton's
team, Santiago Perez, also tested positive. (He did not show up for his
hearing and was pronounced guilty in absentia.)
"It seems inconceivable to me that there would be two people who
were rare chimeras on the same cycling team," Dr. Brown wrote by e-mail.
Dr. Olivier Rabin, the scientific director of the World Anti-Doping
Agency, said the onus was on Mr. Hamilton to prove he was innocent. "It
is up to the defending party to prove it is anything other than blood
doping," he said.
The story of Mr. Hamilton's scientific defense began last September,
when the blood doping allegations were first made public. He had just
won a gold medal in the Athens Olympics and had competed in a bicycle
race in Spain when the World Anti-Doping Agency said his blood revealed
transfusions.
"I was so calm," Mr. Hamilton recalled, thinking the result was a
mistake. "I knew something was wrong and we would get to the bottom of
it."
The next morning, Dr. David Housman, a molecular biology professor at
the Massachusetts Institute of Technology and an avid Red Sox fan, was
reading the sports pages for baseball news and came across an article
on Mr. Hamilton.
Dr. Housman, who never took much interest in bicycle racing, was jolted
by what he read.
"I read it and said: 'Wait a second. I don't think the explanation they
give for the blood test is the only possible explanation,' " he said.
He knew the science showing that chimeras are not so unusual. And
he knew that stem cells turn off and on throughout life so that a stem
cell from a twin, for example, might be producing red blood cells and
then stop, making a tiny amount of foreign blood come and go at random.
So Dr. Housman looked up Mr. Hamilton's father, Bill, on the Internet
and wrote him a letter offering to help, for no fee.
Bill Hamilton was astonished.
"We were so grateful," he said. "At the time, we didn't know which way
to turn, and then out of the blue came this brilliant scientist from
M.I.T. wanting to help."
Not only was a vanishing twin or chimerism a real possibility,
Dr. Housman decided, but he had real questions about whether the test
was reliable enough to use to look for blood doping.
Dr. S. Gerald Sandler, a professor of medicine and pathology at
Georgetown University Hospital, who previously was medical director for
the national reference laboratory for blood group serology at the
National Red Cross and who has no involvement in the Hamilton case,
said the test was acceptable for research. But, he said, its results
could easily differ from lab to lab. It "is being misapplied," he said,
when it is used to accuse athletes of blood doping.
Dr. V. K. Gadi, a hematologic oncologist at the Fred Hutchinson
Cancer Center in Seattle, who uses flow cytometry in his research, says
that "the test can be quite finicky from experiment to experiment," and
that the results can vary depending on how the experimenter sets up the
test.
But the two arbitrators who ruled against Mr. Hamilton said they were
confident that the test was accurate. Although, they wrote, "There are
no scientific studies that detect false positives in the use of the
HBTT," referring to the test, "there is no need to do so because there
is no suggestion in the use of the HBTT that it produces false
positives."
Mr. Hamilton hopes to be vindicated on appeal. In the meantime,
preparing to race again, he is training in Boulder, Colo. After riding
for four to seven hours a day he e-mails his training files to a coach
in Italy who oversees his program.
Bicycling, his wife, Haven, said, is his life. "He still loves
it," she said.
http://www.nytimes.com/2005/05/10/health/10bloo.html?pagewanted=print